Image pharmaphorum Editor News Indivior's once-monthly schizophrenia injection gets US gree... Regulators authorities in the US have approved Indivior’s long-acting injectable treatment for adults with schizophrenia. News GSK's Nucala unlikely to get COPD use after panel vote FDA due to make decision in September News PureTech to research Alzheimer's drugs based on 'brain drain... US biotech PureTech Health is to develop therapies that are based on a new theory that neurological diseases such as Alzheimer’s are linked to drainage issues in the brain. News Philanthropists donate $30m towards finding Alzheimer’s cure A coalition of philanthropists has announced they are donating more than $30 million in a drive to combat Alzheimer’s disease. Load more results
News Indivior's once-monthly schizophrenia injection gets US gree... Regulators authorities in the US have approved Indivior’s long-acting injectable treatment for adults with schizophrenia.
News PureTech to research Alzheimer's drugs based on 'brain drain... US biotech PureTech Health is to develop therapies that are based on a new theory that neurological diseases such as Alzheimer’s are linked to drainage issues in the brain.
News Philanthropists donate $30m towards finding Alzheimer’s cure A coalition of philanthropists has announced they are donating more than $30 million in a drive to combat Alzheimer’s disease.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.